179 related articles for article (PubMed ID: 33712744)
1. Signals of hope: gauging the impact of a rapid national vaccination campaign.
Shilo S; Rossman H; Segal E
Nat Rev Immunol; 2021 Apr; 21(4):198-199. PubMed ID: 33712744
[TBL] [Abstract][Full Text] [Related]
2. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
3. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccine impact in Israel and a way out of the pandemic.
Leshem E; Wilder-Smith A
Lancet; 2021 May; 397(10287):1783-1785. PubMed ID: 33964221
[No Abstract] [Full Text] [Related]
5. Israel's high case plateau may offer worrisome portent.
Wadman M
Science; 2021 Sep; 373(6562):1428-1429. PubMed ID: 34554791
[No Abstract] [Full Text] [Related]
6. BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign.
Ben-Tov A; Banon T; Chodick G; Kariv R; Assa A; Gazit S;
Gastroenterology; 2021 Nov; 161(5):1715-1717.e1. PubMed ID: 34224740
[No Abstract] [Full Text] [Related]
7. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
8. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
Amit S; Regev-Yochay G; Afek A; Kreiss Y; Leshem E
Lancet; 2021 Mar; 397(10277):875-877. PubMed ID: 33610193
[No Abstract] [Full Text] [Related]
9. Israel's grim warning: Delta can overwhelm shots.
Wadman M
Science; 2021 Aug; 373(6557):838-839. PubMed ID: 34413215
[No Abstract] [Full Text] [Related]
10. Key populations for early COVID-19 immunization: preliminary guidance for policy.
Ismail SJ; Zhao L; Tunis MC; Deeks SL; Quach C;
CMAJ; 2020 Nov; 192(48):E1620-E1632. PubMed ID: 33144317
[No Abstract] [Full Text] [Related]
11. Blunting COVID-19's negative impact: Lessons from Israel's vaccination campaign.
Tsigaris P; Teixeira da Silva JA
Travel Med Infect Dis; 2021; 41():102029. PubMed ID: 33737163
[No Abstract] [Full Text] [Related]
12. Equitable global access to coronavirus disease 2019 vaccines.
Schwartz JL
BMJ; 2020 Dec; 371():m4735. PubMed ID: 33323384
[No Abstract] [Full Text] [Related]
13. Impact of national Covid-19 vaccination Campaign, South Korea.
Yi S; Choe YJ; Lim DS; Lee HR; Kim J; Kim YY; Kim RK; Jang EJ; Lee S; Park E; Kim SJ; Park YJ
Vaccine; 2022 Jun; 40(26):3670-3675. PubMed ID: 35570077
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 dynamics after a national immunization program in Israel.
Rossman H; Shilo S; Meir T; Gorfine M; Shalit U; Segal E
Nat Med; 2021 Jun; 27(6):1055-1061. PubMed ID: 33875890
[TBL] [Abstract][Full Text] [Related]
15. How many lives do COVID vaccines save? Evidence from Israel.
Arbel R; Moore CM; Sergienko R; Pliskin J
Am J Infect Control; 2022 Mar; 50(3):258-261. PubMed ID: 34971714
[TBL] [Abstract][Full Text] [Related]
16. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
17. A global database of COVID-19 vaccinations.
Mathieu E; Ritchie H; Ortiz-Ospina E; Roser M; Hasell J; Appel C; Giattino C; Rodés-Guirao L
Nat Hum Behav; 2021 Jul; 5(7):947-953. PubMed ID: 33972767
[TBL] [Abstract][Full Text] [Related]
18. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign.
Meyers E; De Rop L; Deschepper E; Duysburgh E; De Burghgraeve T; Van Ngoc P; Digregorio M; Delogne S; Coen A; De Clercq N; Buret L; Coenen S; De Sutter A; Scholtes B; Verbakel JY; Cools P; Heytens S
Eur J Gen Pract; 2023 Dec; 29(2):2149732. PubMed ID: 36440533
[TBL] [Abstract][Full Text] [Related]
20. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
[No Abstract] [Full Text] [Related]
[Next] [New Search]
